Valeritas ’ V-Go wins preferred status on Humana’s Medicare formularies

Valeritas (NSDQ:VLRX) said today that its V-Go insulin delivery device won preferred status on Humana’s Part D formularies.
The Bridgewater, N.J.-based company’s device is designed for people with Type 2 diabetes. Worn like a patch, the V-Go product delivers a continuous preset basal rate of insulin over 24 hours and can also provide on-demand bolus dosing at meals.
Get the full story at our sister site, Drug Delivery Business News.
The post Valeritas’ V-Go wins preferred status on Humana’s Medicare formularies appeared first on MassDevice.

Source: Mass Device - January 3, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Pharmaceuticals Wall Street Beat Valeritas Source Type: news